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ABSTRACT 
Background: Studies report inconsistent performance characteristics of fecal immunochemical 
tests (FITs) for both colorectal cancer (CRC) and advanced adenomas. 
Purpose: To summarize test characteristics of fecal immunochemical tests (FITs) for CRC and 
advanced adenomas in average-risk persons undergoing screening colonoscopy (reference 
standard) and identify factors affecting these characteristics. 
Data Sources: Ovid MEDLINE, PubMed, Embase, and the Cochrane Library from database 
inception through October 2018; reference lists of studies and reviews.  
Study Selection: Two reviewers independently screened records to identify published English-
language prospective or retrospective observational studies that evaluated FIT sensitivity and 
specificity for colonoscopy findings in asymptomatic average-risk adults. 
Data Extraction: Two authors independently extracted study data and evaluated study quality. 
Data Synthesis: We included 31 studies (120,255 participants, 17 FITs), all of which we judged 
had low-to-moderate risk for bias. Performance characteristics depended on the threshold for a 
positive test. A test threshold of 10 µg/g feces resulted in a CRC sensitivity of 0.91 (95% CI, 
0.84 to 0.95) and negative likelihood ratio of 0.10 (CI, 0.06 to 0.19), while a threshold of > 20 
µg/g resulted in CRC specificity of 0.95 (CI, 0.94 to 0.96) and positive likelihood ratio of 15.49 
(CI, 9.82 to 22.39). Advanced adenoma sensitivity was 0.40 (CI, 0.33 to 0.47) and negative 
likelihood ratio was 0.67 (CI, 0.57 to 0.78) at 10 µg/g, while specificity was 0.95 (0.94 to 0.96) 
and positive likelihood ratio was 5.86 (CI, 3.77-8.97) at > 20 µg/g. There was low-to high 
heterogeneity among studies, depending on threshold. While several FITs had adequate test 
performance, CRC sensitivity and specificity for one qualitative FIT were 90% and 91%, 
respectively, at its single threshold of 10 µg/g, with positive and negative likelihood ratios of 
10.13 and 0.11, respectively. Comparison of performance of 3 FITs at 3 thresholds was 
inconclusive: CIs overlapped and the comparisons were across, rather than within, studies.     
3 
 
Limitations: Only English-language studies were included; incomplete reporting limited quality 
assessment of some evidence. Test characteristics are for one-time, rather than for serial, 
testing. 
Conclusion: Single-application FITs have moderate-to-high CRC sensitivity and specificity 
depending on the positivity threshold. Sensitivity of one-time testing for advanced adenomas is 
low regardless of threshold.  
 
Primary Funding Source: Department of Medicine, Indiana University School of Medicine. 
  
4 
 
BACKGROUND 
 
Colorectal cancer (CRC) is a leading cause of death among digestive diseases and the second 
leading cause of cancer related death in the United States (1). Despite the effectiveness and 
cost-effectiveness of screening (2-4), just 60-65% of the screen-eligible population is current 
with screening (5), a rate that has fallen short of the targeted goal of 80% by 2018 (2, 5, 6). To 
some extent, this shortcoming represents concern over the best test and strategy for screening.  
Although screening colonoscopy is the most frequently used test in the U.S. (5), several other 
countries screen with annual or biennial stool blood tests or a combination of stool testing and 
lower endoscopy (7, 8).  
 
While studies show guaiac-based fecal occult blood testing (gFOBT) reduces CRC incidence 
and mortality (9-13), gFOBT has several shortcomings. Limitations include low single-
application sensitivity for CRC, poor detection of advanced adenomas, the need for dietary and 
medication restrictions, and requirement of more than one specimen.  Fecal immunochemical 
testing (FIT) of stool for human globulin is more sensitive and specific than gFOBT for colorectal 
cancer and advanced adenomas, and has higher rates of participation and acceptance (14-16). 
Studies evaluating the test characteristics of FIT, however, show inconsistent findings for CRC 
and advanced adenomas, the latter of which includes adenomas > 1 cm and those with villous 
histology and/or high-grade dysplasia. A systematic review published in 2014 summarized FIT 
test performance for CRC (17), but did not quantify test characteristics for advanced adenomas. 
The objectives of this systematic review and meta-analysis are to: update the summarization of 
FIT performance for CRC; quantify FIT test characteristics for advanced adenomas; and 
evaluate whether variation in reported test characteristics among studies is a function of the 
threshold used to define a positive test or of the specific test brand. 
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METHODS 
 
Rather than develop and register a new formal protocol, we used two prior systematic reviews 
as guides for our study methodology (17, 18). We followed standard procedures for systematic 
reviews and reported results according to PRISMA (Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses) guidelines (19, 20).PLEASE USE THE 2009 ANNALS PRISMA 
STATEMENT article for this reference. 
 
Data Sources and Searches  
We did English-language literature searches of the MEDLINE, EMBASE, and Cochrane 
databases from inception to 17 October 2018 to identify studies assessing test performance of 
one or more FITs. Searches were done using various combinations of the following terms: 
feces, occult blood, colon cancer, cancer screening, early diagnosis, immunochemistry, and FIT 
(See Appendix Table 1).  We also reviewed reference lists of relevant systematic reviews and 
meta-analyses (17, 18) and of articles that met selection criteria.  
Study Selection 
 Two authors independently screened all titles and potentially relevant abstracts, and then full 
texts of articles that we thought were potentially eligible. Inclusion criteria were published 
English-language prospective or retrospective observational studies that evaluated FIT 
sensitivity and specificity in asymptomatic average-risk adults and that used colonoscopy as the 
reference standard. Data available only in abstract form and grey literature were not eligible.   
 
Data Extraction and Quality Assessment 
Two reviewers reviewed descriptive and quantitative data from each study. Data extraction was 
done primarily by author RG and independently validated by authors TI or TE.  For each study, 
we extracted data on sample size, mean age, brand(s) of FIT used, thresholds for positivity 
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(expressed as micrograms [µg] of hemoglobin per gram [g] of feces), numbers of participants 
with CRC and AA, and test characteristics for CRC and advanced adenomas. When available, 
raw data on CRC and advanced adenomas were extracted.  When only computed data were 
available, individual raw data were calculated based on identified proportions. When data were 
missing from articles, the corresponding authors were contacted. When more than one FIT 
cutoff or threshold was used, test characteristics for thresholds commonly used were extracted.  
Two authors (among TI, RG, and TE) independently assessed study characteristics and 
evaluated study quality by using the revised version of the Quality Assessment of Diagnostic 
Accuracy Studies (QUADAS)-2 tool (21). Discrepancies between reviewers for study quality 
assessment were resolved by discussion. 
 
Data Synthesis and Analysis  
Sensitivity and specificity at one or more threshold were reported for each study.  We combined 
studies and report results for both CRC and advanced adenomas, based on test threshold, in 
micrograms of hemoglobin per gram of feces, where we grouped studies with FIT thresholds of 
< 10 µg/g, 10 µg/g, > 10 to < 20 µg/g, 20 µg/g, and > 20 µg/g. To assess statistical 
heterogeneity, we quantified the I2 measure, which indicates the percentage of total variation 
across studies due to heterogeneity rather than chance (22). For all summary-level estimates, 
we used a bivariate generalized linear mixed model to simultaneously estimate pooled 
measures of sensitivity and specificity separately for both CRC and advanced adenomas while 
accounting for the potential correlation between sensitivity and specificity. The bivariate 
approach produces unbiased estimates of sensitivity, specificity and their correlation (23) and 
does not rely on an ad hoc continuity correction for zero marginal counts. Likelihood ratios (LR) 
were calculated using the bivariate estimates as follows: [LR+ = sensitivity / (1 – specificity); LR- 
= (1 – sensitivity) / specificity]. Summary receiver-operating characteristic curves (SROC) were 
obtained along with 95% confidence regions for the bivariate estimates of sensitivity and 1-
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specificity.  We also combined studies by brand of FIT and did so by threshold to enable indirect 
comparisons.  
 
Meta-Disc software (Hospital Universitario Ramón y Cajal) (24) was used to provide the I2 
measure. For all other summary estimates of test characteristics, the glmer function (25) of the 
lme4 package (26) for R (R Foundation for Statistical Computing) (27) was used to estimate the 
bivariate generalized mixed models. 
 
Role of the Funding Source  
The study was funded by the Department of Medicine and the Melvin & Bren Simon Cancer 
Center at the Indiana University School of Medicine and by the Regenstrief Institute, Inc. These 
funding sources had no role in the conception, design, conduct, analysis, or review of the 
manuscript or the decision to submit it for publication.  
 
RESULTS 
 
 
Our search strategy (Appendix Table 1) generated 4976 citations, of which 31 articles were 
included in the analysis (Figure 1) (Appendix Table 2) (28-58). Studies were published between 
2001 and 2018. Funding sources included federal government (n=15), private or intramural 
(n=4), and corporate (n=2) sources, and were not reported for 10 studies. Participant sample 
size from all studies totaled 120,255 and ranged from 284 to 21,805. Mean age ranged from 
48.2 years to 64 years. All study populations were composed of asymptomatic, mostly average-
risk persons in the screening age range (generally 50 to 75 years old) who enrolled in cancer 
prevention programs of screening colonoscopy. Persons with prior colorectal neoplasia, 
inflammatory bowel disease, high-risk family history, or colonoscopy within the previous 5-10 
years were excluded, as were (post-hoc) those in whom bowel prep quality was unacceptable or 
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extent of colonoscopy incomplete.  
 
Eighteen different FITs were tested, ranging from one to six FITs tested in a single study.  OC 
Sensor (Eiken Chemical Co., LTD) was tested in 14 (58%) studies (35, 39-42, 46-49, 51, 52, 54, 
56, 57), including OC-FIT-CHEK (Eiken Chemical Co., LTD) in two (48, 57) of those 14 studies, 
OC Light (Eiken Chemical Co., LTD) in 5 studies (29, 36, 37, 43, 45), and OC Hemodia (Eiken 
Chemical Co., LTD) and FOB-Gold (Sentinel Diagnostics) in 3 studies each (28, 30, 32, 33, 55, 
58). Many of the remaining FITs are or were available only within a single country or region. 
Thresholds for positivity ranged from 2 µg hemoglobin per gram (g) of feces to 67 µg/g feces, 
with 10 studies using a positivity threshold of < 10 µg/g, 16 studies using a threshold of 10 µg/g, 
8 studies using a threshold of 11-19 µg/g, and 26 studies using a threshold of ≥ 20 µg/g.  
 
FIT test characteristics for CRC and advanced adenomas based on each threshold tested for 
individual studies are shown in Appendix Table 2.  All studies assessed the sensitivity and 
specificity of one or more FITs for advanced adenoma, which ranged in prevalence from 1.26% 
to 12.2%, while all but three studies (33, 39, 51) did so for CRC, which ranged in prevalence 
from 0.15% to 3.48%.  
 
We judged the quality of most studies as high (Appendix Figure 1).  All were cross-sectional. 
Only one used a prospective case-control design (46); for this study, we utilized data only from 
the control group, which, like the other studies, was composed of persons undergoing screening 
colonoscopy. A lack of detail in study methods precluded knowing whether a consecutive or 
random sample of persons participated for nearly half of the studies. Despite this, we assessed 
most studies as having low-to moderate risk for selection bias.  For approximately 30% of the 
studies it was unclear whether FIT results and colonoscopic findings were interpreted 
independently of one another. For 25% of the studies, the interval between FIT and 
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colonoscopy was not specified.   
 
The studies tested one or more FITs; several studies used more than one threshold with the 
objective of determining the optimal threshold. FIT was collected prior to colonoscopy in all but 
one study,(49) which provided no information. While five studies did not specifically state that 
the FITs were interpreted without knowledge of the colonoscopic findings (28, 33, 39, 49, 56), 
FIT processing was automated, making it unlikely that FIT interpretation was biased by the 
findings. Colonoscopy was the reference standard in all studies. In 20 (65%) of 31 articles (29, 
31, 33-38, 41-48, 50, 51, 54, 58), authors reported that colonoscopy was performed blinded to 
FIT results, while authors of 11 articles (28, 30, 32, 39, 40, 49, 52, 53, 55-57) made no comment 
about blinding. Overall, we assessed the risk for bias in interpretation of colonoscopic findings 
due to FIT results to be low. Several studies had post-hoc exclusions of subjects due to not 
completing colonoscopy or FIT, unsatisfactory quality of bowel preparation, incomplete 
colonoscopy, or other reasons. (Appendix Table 3). Only 3 studies provided information on 
indeterminate FITs and for only one of three studies was it clear that test results were truly 
indeterminate (Appendix Table 3). The number of participants excluded due to an unsatisfactory 
colonoscopy was provided in nearly half of the studies and ranged from 0.12% to 8.9%.The risk 
for biased patient flow affecting validity of FIT test characteristics was assessed to be low 
(Appendix Figure 1).  
 
Overall test characteristics of FIT 
 I2 values for heterogeneity were in the low-to-high range for sensitivity and were high for 
specificity for all FIT thresholds for both CRC and AA (Appendix Table 4). Figures 2 and 3 show 
the main results for FIT sensitivity, specificity, and likelihood ratios for CRC and advanced 
adenoma, respectively. Among 31 studies that included a total of 58 assessments of several 
FITs at various thresholds, CRC sensitivity ranged from 91% (CI, 84 to 95%) for a threshold of 
10 
 
10 µg/g feces to 71% (CI, 56 to 83%) for a threshold of > 20 µg/g, while specificity ranged from 
90% (CI, 81 to 95%) for a threshold of < 10 µg/g feces to 95% (CI, 94 to 96%) for a threshold of 
≥ 20 µg/g (Figure 2). Corresponding likelihood ratios ranged from a positive likelihood ratio of 
15.49 at a threshold of > 20 µg/g to a negative likelihood ratio of 0.10 at a threshold of 10 µg/g.  
Among 64 assessments of several different FITs for advanced adenoma, sensitivity ranged from 
40% (CI, 33 to 47%) for a threshold of 10 µg/g to 25% (CI, 20 to 31%) for a threshold of 20 µg/g, 
while specificity ranged from 90% (CI, 87 to 93%) for a threshold of 10 µg/g to 95% (CI, 94 to 
96%) for a threshold of ≥ 20 µg/g feces (Figure 3).  Positive likelihood ratios ranged from 3.39 at 
a threshold of < 10 µg/g to 5.58 at a threshold of > 20 µg/g, while the range for negative 
likelihood ratios was 0.67 to 0.79.  Summary receiver operating characteristics curves and 95% 
confidence regions of the two parameters are displayed in Appendix Figure 2.  For thresholds of 
10 µg/g, >10 to < 20 µg/g and 20 µg/g, respective areas under the curve were 0.94 for CRC at 
all three thresholds and were 0.73, 0.62, and 0.69 for advanced adenoma.   
 
Subgroup analyses based on FIT brand and threshold 
Subgroup analyses are shown in Appendix Figures 3-6, which are displayed separately for three 
individual brand FITs for both CRC and advanced adenoma, and in combination for the 
remaining FITs.  Results are most robust for OC Sensor because of the number of assessment 
made at each of 4 thresholds and for OC Light because of 5 assessments made at its single 
threshold of 10 µg/g feces. CRC sensitivity of OC Sensor ranged from 73% (CI, 48 to 89%)  for 
a threshold > 20 µg/g to 86% (CI, 75 to 93%) for a threshold of ≤ 10 µg/g, while specificity 
ranged from 95% (CI, 94 to 96%) to 90% (CI, 86 to 93%) for the same respective thresholds 
(Appendix Figures 3a). Positive likelihood ratios ranged from 8.45 to 14.71, while negative 
likelihood ratios ranged from 0.15 to 0.28. Advanced adenoma sensitivity ranged from 33% at 
the lowest threshold to 23% at the highest threshold, with corresponding specificities of 91% 
and 95% (Appendix Figure 3b). Positive and negative likelihood ratios had a narrower range for 
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advanced adenoma: 3.66 to 4.46 and 0.73 to 0.81, respectively. For OC Light’s single threshold 
of 10 µg/g,  CRC sensitivity and specificity were 90% and 91%, respectively; for advanced 
adenoma, respective values were 43% (CI, 24 to 66%) and 91% (CI, 83 to 95%) (Appendix 
Figures 4a and 4b). OC Light’s positive and negative likelihood ratios for CRC were 10.13 and 
0.11, respectively. Aggregate point estimates for OC Hemodia, based on 1 or 2 studies, were 
less robust (Appendix Figures 5a and 5b). For the remaining FITs, test characteristics by FIT 
threshold are shown in Appendix Figures 6a and 6b.  
 
For thresholds of 10 µg/g, 11-19 µg/g, and 20 µg/g, Table 2 compares test characteristics for 
five FIT brands, 3 of which are based on 1 or 2 studies. The most robust data at all three 
thresholds exists for OC sensor. At a threshold of 10 µg/g, sensitivity for both CRC and 
advanced adenoma were highest and overlapped among the four brands compared.  Specificity 
at this cutoff for both CRC and advanced adenoma was numerically highest for OC Hemodia, 
with a 95% CI that overlapped only with OC Light.  At the threshold between 10 µg/g and 20 
µg/g, there were large numerical differences in CRC sensitivity (although with overlapping CIs) 
among OC Sensor, OC Hemodia, and FOB Gold, while CRC specificity was nearly identical for 
OC Sensor and FOB Gold (and both higher than for OC Hemodia). Differences among the three 
brands were smaller for advanced adenoma sensitivity.  At a threshold of 20 µg/g, CRC 
sensitivity was numerically higher for FOB Gold, although CIs overlapped with OC Sensor, while 
advanced adenoma sensitivity was lower for OC Hemodia. Advanced adenoma specificity at 
this threshold was nearly identical among the four FITs.  This analysis was limited by a small 
number of studies for some brands and by a comparison that is based on different participants 
which limits inference about relative performance.  
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DISCUSSION 
This systematic review and meta-analysis quantifies and compares FIT test characteristics for 
both CRC and advanced adenoma at 5 different thresholds, and for 3 of them, compares test 
characteristics among different brands of FITs among 31 cross-sectional studies in which 
screening colonoscopy was the reference standard. We found that positivity threshold has a 
greater effect on sensitivity and negative likelihood ratios than on specificity and positive 
likelihood ratios. At a threshold of 10 µg/g, sensitivity for CRC is as high as 91%, specificity is 
90%, with positive and negative likelihood ratios of 9.19 and 0.10, respectively, magnitudes that 
are considered to have clinically important effects on diagnostic threshold (59). Sensitivities for 
advanced adenoma are much lower, ranging from 25-40%, with more modest likelihood ratios. 
Based on the number of studies and either comparability or numerical superiority to other FITs, 
it appears that OC-Sensor (a quantitative FIT) and OC-Light (a qualitative FIT) may be the 
preferred FITs for hospital- and clinic-based testing, respectively, for large- and small-scale use.   
Studies varied by sample size, country, population setting, and age range, as well as FIT used, 
both the brand of test itself and its threshold, with several studies examining multiple thresholds. 
All study populations were composed of asymptomatic and largely average risk persons who 
elected to undergo screening colonoscopy as part of a health promotion / disease prevention 
program on a local, regional, or national level. Prevalence of both CRC and advanced adenoma 
varied among studies. This variation was likely related to the age of study participants and 
perhaps to the country or geographic region where the study was conducted. The exact extent 
to which study populations and disease prevalence affected study findings is difficult to 
determine, since FIT brand and threshold values vary as well.  At any single threshold, 95% 
confidence limits overlap for nearly all studies for both CRC and advanced adenoma, 
suggesting that positivity thresholds, rather than disease prevalence, were associated with 
individual study test characteristics.  
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Our quantitative results do not include a single, overall summary estimate of sensitivity and 
specificity from all studies and all thresholds, as this estimate would have limited clinical utility; 
while it might represent the “best” single estimate across all studies with their varying 
thresholds, it would not necessarily apply to any single FIT at any single threshold. Further, this 
analysis cannot provide optimal test thresholds for CRC screening, as “optimal” requires 
consideration of other factors, among which are colonoscopy resources available to investigate 
positive FIT results and the closely-related false-positive rate. For CRC alone, the optimal 
threshold for a positive test might be between 10 µg/g and 20 µg/g (with a false positive rate of 
7%) or ≥ 20 µg/g (with a false positive rate of 5%), the former threshold increasing colonoscopy 
resources for false-positive results alone by 40%.  Both categories have positive likelihood 
ratios of > 10 and respective negative likelihood ratios of 0.20 and 0.30. Considering both CRC 
and advanced adenoma, either of the same two categories of test thresholds would appear to 
be optimal, but require a consideration of the tradeoffs between them.  
 
Our findings are consistent with two prior systematic reviews that informed our study methods 
(17, 18), one of which quantified performance characteristics for CRC only and included studies 
with the less accurate and potentially biased surrogate reference standard of two-year follow-up 
without a CRC diagnosis (17). The other systematic review quantified performance 
characteristics for both CRC and advanced adenoma, but only included studies of high-risk 
persons (18). In addition, our searches identified a recent systematic review by Gies and 
colleagues that assessed seven FIT brands across 22 studies (60). Although less 
comprehensive than ours and despite inclusion of at least one study that contained persons with 
previous neoplasia (61), Gies and colleagues found areas under receiver operating 
characteristics curves similar to our findings, and determined that the large degree of 
heterogeneity reflected variations in test thresholds (60). Our findings are also consistent with a 
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recent analysis by Selby and colleagues that considered repeated (i.e., programmatic) testing 
with FIT, quantifying CRC detection at various test thresholds (62). These investigators found 
that programmatic sensitivity was greater at lower thresholds, but resulted in a higher number of 
positive test results per cancer detected.   
This study has several limitations that require comment.  While we were able to assess several 
of the QUADAS-2 study quality criteria, a lack of detail in study methods precluded knowing the 
following for several studies: whether a consecutive or random sample of persons participated; 
whether FIT results and colonoscopic findings were interpreted independently of one another; 
and the interval between FIT and colonoscopy.  We did not include non-English studies, which 
could result in language bias, nor did we assess for publication bias.  From a clinical 
perspective, these summary-level performance characteristics apply to one-time testing rather 
serial testing; therefore, the results do not apply to the serial testing that is recommended in 
clinical practice.  Further, we were unable to determine FIT performance characteristics for 
proximal and distal lesions separately. Zorzi and colleagues showed lower programmatic FIT-
based screening for advanced neoplasia in the proximal colon, highlighting the need to 
understand the degree of differential FIT performance (63). Statistical heterogeneity was 
moderate or high for all analyses of specificity and for all analyses for sensitivity except for the 
10 µg/g threshold for CRC, for which heterogeneity was low. Given that the subgroup summary 
estimates show performance characteristics that vary as expected based on positivity threshold, 
the generally high degree of statistical heterogeneity of this systematic review is more likely due 
to the large sample sizes of the individual studies than to clinically important variation in study 
populations, particularly since the outcomes of CRC and advanced adenoma were common to 
all studies.  
This systematic review suggests directions for subsequent research on FIT, the most relevant of 
which is the need for a head-to-head comparison of different FITs examined at various 
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thresholds for both CRC and advanced adenoma, and subgrouped by proximal and distal 
locations of these lesions. While such a study would be challenging logistically and would 
require a very large sample size, it may be feasible within the framework of a regional or 
national screening colonoscopy program. The study would ensure use of the same stool sample 
and standardized pre-analytical conditions. Other studies for consideration include an analysis 
of programmatic performance characteristics based on the number of rounds of FIT and for 
prioritizing colonoscopy resources, a quantitative analysis of the yield of FIT when combined 
with risk factors for advanced colorectal neoplasia.   
In conclusion, this systematic review provides new information about the test characteristics of 
FIT for both CRC and advanced adenoma as a function of test threshold. The findings suggest 
that FIT may be highly sensitive for CRC in a single application, although at the expense of a 
high false-positive rate. At high specificity, FIT is moderately sensitive for CRC. While FIT is 
much less sensitive for advanced adenoma, the natural history of this lesion suggests annual 
transition rates to CRC in the range of 3-6% (64), implying opportunity to detect this lesion with 
programmatic screening.  Health care systems need to consider both quantity and quality of 
data for a specific FIT, comparability of its population to the study populations for that particular 
FIT, and the clinical and economic effects of different test thresholds on colonoscopy and 
systems resources, as consideration of these factors is required to optimize FIT for the early 
detection and prevention of CRC.   
 
  
16 
 
ACKNOWLEDGEMENTS 
None. 
 
FUNDING 
Department of Medicine and the Melvin & Bren Simon Cancer Center at the Indiana University 
School of Medicine and by the Regenstrief Institute, Inc. 
 
AUTHORS ADDRESSES 
Thomas F. Imperiale, MD  
1101 W. 10th St.  
Regenstrief Institute HSR 
Indianapolis, IN 46202 
timperia@iu.edu  
 
Rachel N. Gruber, MS  
1101 W. 10th St.  
Regenstrief Institute HSR 
Indianapolis, IN 46202 
gruberra@regenstrief.org  
 
Timothy E. Stump, MA  
410 W. 10th Street  
HITS 3000  
Indianapolis, IN 46202 
tstump@iu.edu  
 
Thomas Emmett, MD  
975 West Walnut St.  
IB 100 
Indianapolis, IN 46202-5121 
temmett@iu.edu  
 
Patrick O. Monahan, PhD 
410 W. 10th Street  
HITS 3000  
Indianapolis, IN 46202 
pmonahan@iu.edu  
 
 
 
17 
 
REFERENCES 
 
1. Peery AF, Dellon ES, Lund J, et al. Burden of gastrointestinal disease in the United States: 
2012 update. Gastroenterol. 2012;143(5):1179-1187 e1173. 
2. Lin JS, Piper MA, Perdue LA, et al. Screening for Colorectal Cancer: Updated Evidence 
Report and Systematic Review for the US Preventive Services Task Force. JAMA. 
2016;315(23):2576-2594. 
3. Sharaf RN, Ladabaum U. Comparative effectiveness and cost-effectiveness of screening 
colonoscopy vs. sigmoidoscopy and alternative strategies. Am J Gastroenterol. 
2013;108(1):120-32. 
4. Heitman SJ, Hilsden RJ, Au F, Dowden S, Manns BJ. Colorectal cancer screening for 
average-risk North Americans: an economic evaluation. PLoS Med. 
2010;7(11):e1000370. 
5. Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average-risk 
adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin. 
2018;68(4):250-281. 
6. Maxwell AE, Hannon PA, Escoffery C, et al. Promotion and provision of colorectal cancer 
screening: a comparison of colorectal cancer control program grantees and 
nongrantees, 2011-2012. Prev Chronic Dis. 2014;11:E170. 
7. Navarro M, Nicolas A, Ferrandez A, Lanas A. Colorectal cancer population screening 
programs worldwide in 2016: An update. World J Gastroenterol. 2017;23(20):3632-
3642. 
8. Altobelli E, D'Aloisio F, Angeletti PM. Colorectal cancer screening in countries of 
European Council outside of the EU-28. World J Gastroenterol. 2016;22(20):4946-57. 
9. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of 
faecal-occult-blood screening for colorectal cancer. Lancet. 1996;348(9040):1472-1477. 
10. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by 
screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 
1993;328(19):1365-1371. 
11. Shaukat A, Mongin SJ, Geisser MS, et al. Long-term mortality after screening for 
colorectal cancer. N Engl J Med. 2013;369(12):1106-1114. 
12. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of 
screening for colorectal cancer with faecal-occult-blood test. Lancet. 
1996;348(9040):1467-71. 
13. Mandel JS, Church TR, Bond JH, et al. The effect of fecal occult-blood screening on the 
incidence of colorectal cancer. N Engl J Med. 2000;343(22):1603-1607. 
14. van Roon AH, Goede SL, van Ballegooijen M, et al. Random comparison of repeated 
faecal immunochemical testing at different intervals for population-based colorectal 
cancer screening. Gut. 2013;62(3):409-415. 
15. van Rossum LG, van Rijn AF, Laheij RJ, et al. Random comparison of guaiac and 
immunochemical fecal occult blood tests for colorectal cancer in a screening population. 
Gastroenterology. 2008;135(1):82-90. 
18 
 
16. Hol L, van Leerdam ME, van Ballegooijen M, et al. Screening for colorectal cancer: 
randomised trial comparing guaiac-based and immunochemical faecal occult blood 
testing and flexible sigmoidoscopy. Gut. 2010;59(1):62-68. 
17. Lee JK, Liles EG, Bent S, Levin TR, Corley DA. Accuracy of fecal immunochemical tests for 
colorectal cancer: systematic review and meta-analysis. Ann Intern Med. 
2014;160(3):171. 
18. Katsoula A, Paschos P, Haidich AB, Tsapas A, Giouleme O. Diagnostic Accuracy of Fecal 
Immunochemical Test in Patients at Increased Risk for Colorectal Cancer: A Meta-
analysis. JAMA Intern Med. 2017;177(8):1110-8. 
19. Institute of Medicine Committee on Standards for Systematic Reviews of Comparative 
Effectiveness R. In: Eden J, Levit L, Berg A, Morton S, eds. Finding What Works in Health 
Care: Standards for Systematic Reviews. Washington (DC): National Academies Press 
(US) Copyright 2011 by the National Academy of Sciences. All rights reserved.; 2011. 
20. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, 
Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic 
reviews and meta-analyses of studies that evaluate health care interventions: 
explanation and elaboration. Ann Intern Med. 2009 Aug 18;151(4):W65-94.  
21. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality 
assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529-536. 
22. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-
analyses. BMJ. 2003;327(7414):557-60. 
23. Chu H, Cole SR. Bivariate meta-analysis of sensitivity and specificity with sparse data: a 
generalized linear mixed model approach. J Clin Epidemiol. 2006;59(12):1331-2; author 
reply 2-3. 
24. Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A. Meta-DiSc: a software for meta-
analysis of test accuracy data. BMC Med Res Methodol. 2006;6(1):31. 
25. Partlett C, Takwoingi Y. Meta-analysis of test accuracy studies in R: a summary of user-
written programs and step-by-step guide to using glmer. Version 1.0. August 2016. 
2018. 
26. Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. J 
Statistical Software. 2015;67(1):1-48. 
27. Team RC. R: A language and environment for statistical computing. 2013. 
28. Nakama H, Zhang B, Zhang X. Evaluation of the optimum cut-off point in 
immunochemical occult blood testing in screening for colorectal cancer. Eur J Cancer. 
2001;37(3):398-401. 
29. Cheng TI, Wong JM, Hong CF, et al. Colorectal cancer screening in asymptomaic adults: 
comparison of colonoscopy, sigmoidoscopy and fecal occult blood tests. J Formos Med 
Assoc. 2002;101(10):685-90. 
30. Sohn DK, Jeong SY, Choi HS, et al. Single immunochemical fecal occult blood test for 
detection of colorectal neoplasia. Cancer Res Treat. 2005;37(1):20-3. 
31. Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y. A comparison of the 
immunochemical fecal occult blood test and total colonoscopy in the asymptomatic 
population. Gastroenterol. 2005;129(2):422-8. 
19 
 
32. Nakazato M, Yamano HO, Matsushita HO, et al. Immunologic fecal occult blood test for 
colorectal cancer screening. Japan Med Assoc J. 2006;49(5-6):203-7. 
33. Graser A, Stieber P, Nagel D, et al. Comparison of CT colonography, colonoscopy, 
sigmoidoscopy and faecal occult blood tests for the detection of advanced adenoma in 
an average risk population. Gut. 2009;58(2):241-8. 
34. Brenner H, Haug U, Hundt S. Inter-test agreement and quantitative cross-validation of 
immunochromatographical fecal occult blood tests. Int J Cancer. 2010;127(7):1643-9. 
35. Park DI, Ryu S, Kim YH, et al. Comparison of guaiac-based and quantitative 
immunochemical fecal occult blood testing in a population at average risk undergoing 
colorectal cancer screening. Am J Gastroenterol. 2010;105(9):2017-25. 
36. Parra-Blanco A, Gimeno-Garcia AZ, Quintero E, et al. Diagnostic accuracy of 
immunochemical versus guaiac faecal occult blood tests for colorectal cancer screening. 
J Gastroenterol. 2010;45(7):703-12. 
37. Chiang TH, Lee YC, Tu CH, Chiu HM, Wu MS. Performance of the immunochemical fecal 
occult blood test in predicting lesions in the lower gastrointestinal tract. CMAJ. 
2011;183(13):1474-81. 
38. Haug U, Kuntz KM, Knudsen AB, Hundt S, Brenner H. Sensitivity of immunochemical 
faecal occult blood testing for detecting left- vs right-sided colorectal neoplasia. Br J 
Cancer. 2011;104(11):1779-85. 
39. Khalid-de Bakker CA, Jonkers DM, Sanduleanu S, et al. Test performance of immunologic 
fecal occult blood testing and sigmoidoscopy compared with primary colonoscopy 
screening for colorectal advanced adenomas. Cancer Prev Res (Phila). 2011;4(10):1563-
71. 
40. Omata F, Shintani A, Isozaki M, Masuda K, Fujita Y, Fukui T. Diagnostic performance of 
quantitative fecal immunochemical test and multivariate prediction model for colorectal 
neoplasms in asymptomatic individuals. Eur J Gastroenterol Hepatol. 2011;23(11):1036-
41. 
41. de Wijkerslooth TR, Stoop EM, Bossuyt PM, et al. Immunochemical fecal occult blood 
testing is equally sensitive for proximal and distal advanced neoplasia. Am J 
Gastroenterol. 2012;107(10):1570-8. 
42. Brenner H, Tao S. Superior diagnostic performance of faecal immunochemical tests for 
haemoglobin in a head-to-head comparison with guaiac based faecal occult blood test 
among 2235 participants of screening colonoscopy. Eur J Cancer. 2013;49(14):3049-54. 
43. Chiu HM, Lee YC, Tu CH, et al. Association between early stage colon neoplasms and 
false-negative results from the fecal immunochemical test. Clin Gastroenterol Hepatol. 
2013;11(7):832-8 e1-2. 
44. Ng SC, Ching JY, Chan V, et al. Diagnostic accuracy of faecal immunochemical test for 
screening individuals with a family history of colorectal cancer. Aliment Pharmacol Ther. 
2013;38(7):835-41. 
45. Chen YY, Chen TH, Su MY, et al. Accuracy of immunochemical fecal occult blood test for 
detecting colorectal neoplasms in individuals undergoing health check-ups. Advances in 
Digestive Medicine. 2014;1(3):74-9. 
20 
 
46. Cubiella J, Castro I, Hernandez V, et al. Diagnostic accuracy of fecal immunochemical 
test in average- and familial-risk colorectal cancer screening. United European 
Gastroenterol J. 2014;2(6):522-9. 
47. Hernandez V, Cubiella J, Gonzalez-Mao MC, et al. Fecal immunochemical test accuracy 
in average-risk colorectal cancer screening. World J Gastroenterol. 2014;20(4):1038-47. 
48. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for 
colorectal-cancer screening. N Engl J Med. 2014;370(14):1287-97. 
49. Stegeman I, de Wijkerslooth TR, Stoop EM, et al. Combining risk factors with faecal 
immunochemical test outcome for selecting CRC screenees for colonoscopy. Gut. 
2014;63(3):466-71. 
50. Aniwan S, Rerknimitr R, Kongkam P, et al. A combination of clinical risk stratification and 
fecal immunochemical test results to prioritize colonoscopy screening in asymptomatic 
participants. Gastrointest Endosc. 2015;81(3):719-27. 
51. Chang LC, Shun CT, Hsu WF, et al. Fecal Immunochemical Test Detects Sessile Serrated 
Adenomas and Polyps With a Low Level of Sensitivity. Clin Gastroenterol Hepatol. 
2016;15(6):872-9 e1. 
52. Chiu HM, Ching JY, Wu KC, et al. A Risk-Scoring System Combined With a Fecal 
Immunochemical Test Is Effective in Screening High-Risk Subjects for Early Colonoscopy 
to Detect Advanced Colorectal Neoplasms. Gastroenterology. 2016;150(3):617-25 e3. 
53. Siripongpreeda B, Mahidol C, Dusitanond N, et al. High prevalence of advanced 
colorectal neoplasia in the Thai population: a prospective screening colonoscopy of 
1,404 cases. BMC Gastroenterol. 2016;16:101. 
54. Aniwan S, Ratanachu-Ek T, Pongprasobchai S, et al. Impact of Fecal Hb Levels on 
Advanced Neoplasia Detection and the Diagnostic Miss Rate For Colorectal Cancer 
Screening in High-Risk vs. Average-Risk Subjects: a Multi-Center Study. Clin Transl 
Gastroenterol. 2017;8(8):e113. 
55. Brenner H, Niedermaier T, Chen H. Strong subsite-specific variation in detecting 
advanced adenomas by fecal immunochemical testing for hemoglobin. Int J Cancer. 
2017;140(9):2015-22. 
56. Kim NH, Park JH, Park DI, Sohn CI, Choi K, Jung YS. The fecal immunochemical test has 
high accuracy for detecting advanced colorectal neoplasia before age 50. Dig Liver Dis. 
2017;49(5):557-61. 
57. Shapiro JA, Bobo JK, Church TR, et al. A Comparison of Fecal Immunochemical and High-
Sensitivity Guaiac Tests for Colorectal Cancer Screening. Am J Gastroenterol. 
2017;112(11):1728-35. 
58. Brenner H, Qian J, Werner S. Variation of diagnostic performance of fecal 
immunochemical testing for hemoglobin by sex and age: results from a large screening 
cohort. Clin Epidemiol. 2018;10:381-9. 
59. Grimes DA, Schulz KF. Refining clinical diagnosis with likelihood ratios. Lancet. 
2005;365(9469):1500-5. 
60. Gies A, Bhardwaj M, Stock C, Schrotz-King P, Brenner H. Quantitative fecal 
immunochemical tests for colorectal cancer screening. Int J Cancer. 2018;143(2):234-44. 
61. Redwood DG, Asay ED, Blake ID, et al. Stool DNA Testing for Screening Detection of 
Colorectal Neoplasia in Alaska Native People. Mayo Clin Proc. 2016;91(1):61-70. 
21 
 
62. Selby K, Jensen CD, Lee JK, et al. Influence of Varying Quantitative Fecal 
Immunochemical Test Positivity Thresholds on Colorectal Cancer Detection: A 
Community-Based Cohort Study. Ann Intern Med. 2018;169(7):439-47. 
63. Zorzi M, Hassan C, Capodaglio G, et al. Divergent Long-Term Detection Rates of Proximal 
and Distal Advanced Neoplasia in Fecal Immunochemical Test Screening Programs: A 
Retrospective Cohort Study. Ann Intern Med. 2018;169(9):602-9. 
64. Brenner H, Hoffmeister M, Stegmaier C, Brenner G, Altenhofen L, Haug U. Risk of 
progression of advanced adenomas to colorectal cancer by age and sex: estimates based 
on 840,149 screening colonoscopies. Gut. 2007;56(11):1585-9. 
 
 
22 
 
FIGURE LEGEND 
Figure 1. Flow diagram of evidence search and study selection 
Figure 2. Summary-level Test Characteristics by FIT threshold for Colorectal Cancer 
Figure 3. Summary-level Test Characteristics by FIT threshold for Advanced Adenoma 
 
 
 
 
Table 1. Comparison of Brand-specific Test Characteristics at Various Thresholds 
 
Test Study N 
/Patients 
with CRC 
Study N 
/Patients 
with AA 
CRC Sensitivity 
(CI) 
CRC Specificity 
(CI) 
AA Sensitivity 
(CI) 
AA Specificity 
(CI) 
CRC Positive 
Likelihood Ratio (95% 
CI) 
CRC Negative 
Likelihood Ratio 
(95% CI) 
AA Positive 
Likelihood Ratio 
(95% CI) 
AA Negative 
Likelihood Ratio 
(95% CI) 
Threshold = 10           
OC Sensor 6 / 56 7 / 898 0.86 (0.75, 0.93) 0.90 (0.86, 0.93) 0.33 (0.30, 0.39) 0.91 (0.86, 0.92) 9.94 (7.07, 12.99) 0.13 (0.06, 0.27) 3.72 (2.87, 4.80) 0.73 (0.69, 0.78) 
OC Light 5 / 99 5 / 1027 0.90 (0.72, 0.97) 0.91 (0.83, 0.95) 0.43 (0.24, 0.66) 0.91 (0.83, 0.95) 10.13 (4.34, 21.01) 0.11 (0.03, 0.34) 4.81 (1.41, 14.11) 0.62 (0.36, 0.92) 
OC Hemodia 1 / 27 1 / 56 0.89 (0.71, 0.98) 0.94 (0.93, 0.95) 0.59 (0.45, 0.72) 0.94 (0.93, 0.95) 14.62 (10.34, 18.17) 0.12 (0.02, 0.31) 9.69 (6.57, 13.38) 0.44 (0.30, 0.59) 
FOB Gold 1 / 25 1 / 286 0.96 (0.80, 1.00) 0.88 (0.87, 0.89) 0.49 (0.43, 0.55) 0.88 (0.87, 0.89) 8.00 (6.02, 9.22) 0.05 (0.00, 0.23) 4.05 (3.22, 5.03) 0.58 (0.51, 0.66) 
Threshold >10 <20           
OC Sensor 4 /34 6 / 702 0.81 (0.55, 0.94) 0.93 (0.91, 0.93) 0.29 (0.25, 0.34) 0.93 (0.92, 0.94) 10.93 (6.46, 14.45) 0.20 (0.06, 0.49) 4.41 (3.16, 6.09) 0.76 (0.70, 0.81) 
OC Hemodia 1 / 19 1 / 53 0.53 (0.29, 0.76) 0.87 (0.86, 0.89) 0.25 (0.14, 0.38) 0.87 (0.86, 0.89) 4.17 (2.08, 6.59) 0.54 (0.28, 0.83) 1.94 (0.99, 3.34) 0.86 (0.70, 1.00) 
FOB Gold 1 / 29 1 / 354 0.97 (0.82, 1.00) 0.94 (0.93, 0.95) 0.37 (0.32, 0.43) 0.97 (0.96, 0.97) 16.45 (12.17, 19.72) 0.04 (0.00, 0.19) 6.35 (4.78, 8.40) 0.67 (0.61, 0.73) 
Threshold = 20           
OC Sensor 11 / 163 12 / 2286 0.77 (0.66, 0.85) 0.94 (0.91, 0.96) 0.26 (0.20, 0.32) 0.95 (0.92, 0.96) 13.88 (7.68, 24.03) 0.24 (0.15, 0.37) 4.70 (2.50, 8.74) 0.79 (0.71, 0.87) 
OC Hemodia 1 / 12 1 / 67 0.25 (0.06, 0.57) 0.96 (0.96, 0.97) 0.06 (0.02, 0.15) 0.96 (0.96, 0.97) 6.98 (1.30, 19.02) 0.78 (0.44, 0.99) 1.67 (0.39, 4.85) 0.98 (0.88, 1.03) 
FOB Gold 1 / 25 1 / 286 0.92 (0.74, 1.00) 0.95 (0.94, 0.96) 0.34 (0.28, 0.40) 0.95 (0.94, 0.96) 17.67 (12.17, 22.37) 0.08 (0.01, 0.28) 6.51 (4.68, 8.97) 0.70 (0.63, 0.76) 
Magstream 1000/Hem SP 1 / 79 1 / 648 0.66 (0.54, 0.76) 0.95 (0.95, 0.95) 0.23 (0.19, 0.26) 0.95 (0.95, 0.95) 13.42 (10.43, 16.49) 0.36 (0.25, 0.48) 4.56 (3.69, 5.58) 0.82 (0.78, 0.85) 
AA: Advanced Adenoma; CI: 95% Confidence Interval; CRC: colorectal cancer 
All results generated using a bivariate model 
 



TECHNICAL APPENDIX  
 
 
The approach of Chu and Cole (2006) was used to calculate summary-level estimates of 
sensitivity and specificity across studies. This approach produces unbiased estimates of 
sensitivity, specificity and their correlation and does not utilize the ad hoc continuity correction of 
zero marginal counts of other methods (Reitsma et al, 2005). To automate the process, an R 
function was created using commands from a tutorial written by Partlett and Takwoingi (2016), 
obtained from the Cochrane methods website (https://methods.cochrane.org/sdt/software-meta-
analysis-dta-studies). 
 
Below is the R function used to obtain estimates for the bivariate generalized mixed models: 
 
runmod <- function(dsn) { 
   
   ### Create temporary dataset based upon dsn argument ### 
   ### note: dsn must contain TP, FN, FP and TN variables ### 
   temp <- as.data.frame(dsn) 
 
   ### Set up the data ### 
   ### Generate 5 new variables of type long. We need these before we can reshape the data. 
   ### These variables will be included in the glmer function call. 
   # n1 is number diseased 
   # n0 is number without disease 
   # true1 is number of true positives 
   # true0 is the number of true negatives 
   # study is the unique identifier for each study. _n will generate a sequence of numbers.   
   temp$n1 <- temp$TP+temp$FN 
   temp$n0 <- temp$FP+temp$TN 
   temp$true1 <- temp$TP 
   temp$true0 <- temp$TN  
   temp$study <- 1:length(temp$n1) 
     
   ### Reshape the data from wide to long format ### 
   long <- reshape(temp, direction = "long",  
                       varying = list( c("n1" , "n0") , c( "true1","true0" )),  
                       timevar = "sens",  
                       times = c(1,0),  
                       v.names = c("n","true"))  
   
   ### Sort data by study to cluster the 2 records per study together ###    
   long <- long[order(long$id),]   
   long$spec<- 1-long$sens 
   
   ### Run glmer model to obtain sensitivity and specificity estimates ### 
   ### note: between study covariance matrix is unstructured 
   y1 <- glmer(formula = cbind(true , n - true) ~ 0 + sens + spec + (0+sens + spec|study), 
               data = long,  
               glmerControl(optimizer="bobyqa", optCtrl = list(maxfun = 100000)), 
               family = binomial) 
   
   ### More detail can be obtained by using the summary command ###  
   s <- summary(y1) 
        
   ### Extract the coefficients from the model ### 
   lsens = s$coeff[1,1] 
   lspec = s$coeff[2,1]  
   
   se.lsens = s$coeff[1,2] 
   se.lspec = s$coeff[2,2]  
   
   ### Create 95% confidence intervals for logit sens and spec ### 
   logit_Sens = c(lsens, lsens-qnorm(0.975)*se.lsens, lsens+qnorm(0.975)*se.lsens )  
   logit_Spec = c(lspec, lspec-qnorm(0.975)*se.lspec, lspec+qnorm(0.975)*se.lspec )  
   
   ### R has a built in logit and inv.logit function (use qlogis and plogis) ### 
   sens <- plogis(logit_Sens)  
   spec <- plogis(logit_Spec)  
 
   ### Create data frame containing sens/spec estimates ### 
   f <- t(data.frame(logit_Sens, sens, logit_Spec, spec)) 
   colnames(f) <- c("mean","low","hi") 
   rownames(f) <- c("logit_Sens","sens","logit_Spec","spec") 
   
   ### Return a list containing model summary and calculated sens/spec estimates ### 
   l <- list(s, f) 
   return(l) 
} 
 
To run this function, you will need to make sure the lme4 library is loaded by running the 
following statement in your R script:  library(lme4) 
 
An example call to this function would be: 
 
crc10_model <- runmod(crc10) 
 
where crc10 is a data frame containing the TP, FP, FN and TN variables. An example would be 
the following:  
 
 
 
  
The returned object from the function is a list containing the model summary as the first element 
and the sens/spec estimates as the second element. An example of the output returned would 
be the following: 
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Appendix Table 1: Detailed Search Strategies 
 
 
MEDLINE (Ovid):  1      exp Feces/ 2      exp Occult Blood/ 3      (feces or faeces or fecal or faecal or stool or occult blood or fob*).tw.  4      exp Colorectal Neoplasms/  5      (colon or colonic or colorectal or colo rectal).tw. 6      exp Mass Screening/ 7      exp "Early Detection of Cancer"/ 8      screen*.tw.  9      (or/4-5) and (or/6-8) 10     Immunochemistry/  11     Immunologic Tests/  12     (immunochem* or immuno chem*).tw.  13     fit.ti.  14     (or/1-3,9) and (or/10-13) 15     ((feces or faeces or fecal or faecal or stool or occult blood or fob*) adj10 (immunologic*  or  immunochromatograph* or immuno chromatograph* or immunohistochem* or immuno  histochem*)).tw.  16     (ifobt or i fobt or immunofecal* or immuno fecal* or immunofaecal* or immuno faecal*).tw.  17     (hemeselect or heme select or hemoccultsensa or hemoccult sensa or immudia or magstream or bayer detect or flexsure or oc auto or (monohaem not cytochrome*) or oc sensor or hemodia or fobgold or sentifob).tw. 18     or/14-17 19     limit 18 to english language  20     exp Animals/ not exp Humans/  21     19 not 20  
PubMed (PubMed.gov):  #1 feces [tiab] OR faeces [tiab] OR fecal [tiab] OR faecal [tiab] OR stool [tiab] OR "occult blood"  [tiab] OR fob* [tiab] #2 (colon [tiab] OR colonic [tiab] OR colorectal [tiab] OR "colo rectal" [tiab]) AND screen* [tiab] #3 immunochem* [tiab] OR immuno chem* [tiab] OR immunologic* [tiab] OR immunochromatograph* [tiab] OR immuno chromatograph* [tiab] OR immunohistochem* [tiab] OR immuno histochem* [tiab] OR fit [ti] #4 ifobt [tiab] OR "i fobt" [tiab] OR immunofecal* [tiab] OR immuno fecal* [tiab] OR immunofaecal* [tiab] OR immuno faecal* [tiab] #5 hemeselect [tiab] OR "heme select" [tiab] OR hemoccultsensa [tiab] OR "hemoccult sensa" [tiab] OR immudia [tiab] OR magstream [tiab] OR "bayer detect" [tiab] OR flexsure [tiab] OR "oc auto" [tiab] OR (monohaem [tiab] NOT cytochrome* [tiab]) OR "oc sensor" [tiab] OR hemodia [tiab] OR fobgold [tiab] OR sentifob [tiab] #6 Search ((#1 OR #2) AND #3) OR #4 OR #5 NOT medline [sb] Filters: English  
EMBASE (Embase.com):  #1  'feces'/exp #2   'occult blood'/exp 
 3 
#3   feces:ab,ti OR faeces:ab,ti OR fecal:ab,ti OR faecal:ab,ti OR stool:ab,ti OR 'occult blood':ab,ti OR fob*:ab,ti #4    'colon cancer'/exp #5    colon:ab,ti OR colonic:ab,ti OR colorectal:ab,ti OR 'colo rectal':ab,ti #6    'cancer screening'/exp #7    'early diagnosis'/exp #8    screen*:ab,ti #9    (#4 OR #5) AND (#6 OR #7 OR #8) #10  'immunochemistry'/de #11   'immunological procedures'/de #12   immunochem*:ab,ti OR (immuno NEXT/1 chem*):ab,ti #13   fit:ti #14   (#1 OR #2 OR #3 OR #9) AND (#10 OR #11 OR #12 OR #13) #15   ((feces OR faeces OR fecal OR faecal OR stool OR 'occult blood' OR fob*) NEAR/10 (immunologic* OR immunochromatograph* OR chromatograph* OR immunohistochem* OR histochem*)):ab,ti #16  ifobt:ab,ti OR 'i fobt':ab,ti OR immunofecal*:ab,ti OR 'immuno fecal':ab,ti OR immunofaecal*:ab,ti OR 'immuno faecal':ab,ti #17   hemeselect:ab,ti OR 'heme select':ab,ti OR hemoccultsensa:ab,ti OR 'hemoccult sensa':ab,ti OR immudia:ab,ti OR magstream:ab,ti OR 'bayer detect':ab,ti OR flexsure:ab,ti OR 'oc auto':ab,ti OR 'oc sensor':ab,ti OR hemodia:ab,ti OR fobgold:ab,ti OR sentifob:ab,ti #18   monohaem:ab,ti NOT cytochrome*:ab,ti #19   #14 OR #15 OR #16 OR #17 OR #18 #20   'animal'/exp NOT 'human'/exp #21   (#19 NOT #20) AND [english]/lim  
Cochrane Library (Wiley):   #1 (feces or faeces or fecal or faecal or stool or "occult blood" or fob*):ti,ab,kw  #2 ((colon or colonic or colorectal or "colo rectal") and screen*):ti,ab,kw  #3 (immunochem* or immuno chem* or immunologic* or immunochromatograph* or immuno chromatograph* or immunohistochem* or immuno histochem*):ti,ab,kw or fit:ti  #4 (ifobt or "i fobt" or immunofecal* or immuno fecal* or immunofaecal* or immuno faecal* or hemeselect or "heme select" or hemoccultsensa or "hemoccult sensa" or immudia or magstream or "bayer detect" or flexsure or "oc auto" or (monohaem not cytochrome*) or "oc sensor" or hemodia or fobgold or sentifob):ti,ab,kw  #5 ((#1 or #2) and #3) or #4  
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Appendix Table 2. Selected Characteristics of Included Studies 
 
Study, Year (ref) Study Type Population Setting Funding Source Cohort 
size, n 
FIT brand Mean age (range) FIT  
samples, 
n  
µg/g Timing of FIT 
relative to 
colonoscopy 
FIT interpreted 
independent of 
colonoscopy 
CRC 
Prevalence 
AA 
Prevalence 
CRC 
Cases, 
n 
AA 
Cases, 
n 
CRC Sensitivity 
(95% CI) 
CRC Specificity 
(95% CI) 
AA Sensitivity 
(95% CI) 
AA Specificity 
(95% CI) 
Nakama 2001 (28) Prospective cross 
sectional 
Hospital based CRC 
screening program 
Ministry of Health 
and Welfare of 
Japan 
4260 OC Hemodia NA (40 to 70+) 2 10 Prior Unknown 0.63% 1.31% 27 56 0.89 (0.71, 0.98) 0.94 (0.93, 0.95) 0.59 (0.45, 0.72) 0.94 (0.93, 0.95) 
     30       0.82 (0.62, 0.94) 0.96 (0.96, 0.97) 0.54 (0.40, 0.67) 0.96 (0.96, 0.97) 
     60       0.56 (0.35, 0.75) 0.97 (0.97, 0.98) 0.21 (0.12, 0.34) 0.97 (0.97, 0.98) 
Cheng 2002 (29) Retrospective 
cross sectional 
Hospital based 
health screening 
program 
Not reported 7411 OC Light 46.8 (≤20 to ≥81)* 1 10 Prior Yes 0.22% 1.04% 16 77 0.88 (0.62, 0.98) 0.92 (0.91, 0.93) 0.40 (0.29, 0.52) 0.92 (0.91, 0.93) 
Sohn 2004 (30)† Prospective cross 
sectional 
Single center cancer 
prevention program 
Not reported 3794 OC Hemodia 48.9 (15 to 78) 1 20 Prior Yes 0.32%  1.77% 12 67 0.25 (0.06, 0.57) 0.96 (0.96, 0.97) 0.06 (0.02, 0.15) 0.96 (0.96, 0.97) 
Morikawa 2005 (31) Retrospective 
cross sectional 
Single center cancer 
prevention program 
Not reported 21805 Magstream 1000/Hem 
SP 
48.2 (21 to 91) 1 20 Prior Yes 0.36%  2.97% 79 648 0.66 (0.54, 0.76) 0.95 (0.95, 0.95) 0.23 (0.19, 0.26) 0.95 (0.95, 0.95) 
Nakazato 2006 (32) Prospective cross 
sectional 
Hospital based CRC 
screening program  
Not reported 3090 OC Hemodia 53.4 (Not provided) 2 16 Prior Yes 0.61%  1.72% 19 53 0.53 (0.29, 0.76) 0.87 (0.86, 0.89) 0.25 (0.14, 0.38) 0.87 (0.86, 0.89) 
Graser 2009 (33) Prospective cross 
sectional 
Hospital based CRC 
screening study 
Not reported 284 FOB Gold 60.5 (50 to 81) 2 3 Prior Unknown NA 8.10% NA 23 NA NA 0.30 (0.13, 0.53) 0.86 (0.81, 0.90) 
Brenner 2010 (34) Prospective cross 
sectional 
Regional 
colonoscopy 
screening program 
German Research 
Foundation 
1330 PreventID 63 (Not provided) 1 2 Prior Yes 0.83%  9.77% 11 130 1.00 (0.72, 1.00) 0.81 (0.79, 0.83) 0.49 (0.40, 0.58) 0.81 (0.79, 0.84) 
  Bionexia Hb/Hp 
Complex 
  5       0.82 (0.48, 0.98) 0.56 (0.54, 0.59) 0.72 (0.63, 0.79) 0.56 (0.54, 0.59) 
  Bionexia   8       1.00 (0.72, 1.00) 0.80 (0.77, 0.82) 0.52 (0.43, 0.61) 0.80 (0.77, 0.82) 
  FOB advanced   8       0.73 (0.39, 0.94) 0.91 (0.90, 0.93) 0.27 (0.20, 0.35) 0.91 (0.90, 0.93) 
  immoCARE-C   10       0.82 (0.48, 0.98) 0.96 (0.95, 0.97) 0.25 (0.18, 0.34) 0.96 (0.95, 0.97) 
  QuickVue iFOB   10       1.00 (0.72, 1.00) 0.68 (0.65, 0.70) 0.56 (0.47, 0.65) 0.68 (0.65, 0.71) 
Park 2010 (35) Prospective cross 
sectional 
Screening 
colonoscopy at 4 
tertiary centers 
Eiken Chemical  & 
Shinyong 
Diagnostics‡ 
770 OC Sensor 59.3 (50 to 75) 3 10 Prior Yes 1.69%  7.66% 13 59 0.92 (0.64, 1.00) 0.90 (0.87, 0.92) 0.44 (0.31, 0.58) 0.90 (0.87, 0.93) 
     15       0.92 (0.64, 1.00) 0.91 (0.90, 0.93) 0.37 (0.25, 0.51) 0.91 (0.90, 0.93) 
     20       0.92 (0.64, 1.00) 0.92 (0.90, 0.93) 0.34 (0.22, 0.47) 0.92 (0.90, 0.94) 
     25       0.85 (0.55, 0.98) 0.93 (0.91, 0.95) 0.29 (0.18, 0.42) 0.93 (0.91, 0.95) 
     30       0.85 (0.55, 0.98) 0.94 (0.92, 0.95) 0.27 (0.16, 0.40) 0.94 (0.92, 0.95) 
Parra-Blanco 2010 
(36) 
Prospective cross 
sectional 
Random sample - 
population based 
screening 
In part by 
Government Grants 
402 OC Light NA (50 to 79) 1 10 Prior Yes 3.48%  12.19% 14 49 1.00 (0.77, 1.00) 0.74 (0.69, 0.79) 0.86 (0.73, 0.94) 0.74 (0.69, 0.79) 
Chiang 2011 (37) Prospective cross 
sectional 
Hospital based 
advertised screening 
program 
Taipei Institute of 
Pathology 
2222 OC Light 49 (19 – 84) 1 10 Prior Yes 1.26%  1.26% 28 28 0.96 (0.82, 1.00) 0.87 (0.86, 0.89) 0.46 (0.28, 0.66) 0.87 (0.86, 0.87) 
Haug 2011 (38) †† Prospective cross 
sectional 
Regional 
colonoscopy 
screening program 
German Research 
Foundation‡ 
2325 RIDASCREEN Hemo NA (Not provided) 1 8 Prior Yes 0.60% 9.20% 13 215 0.77 (0.46, 0.95) 0.95 (0.94, 0.96) 0.27 (0.21, 0.33) 0.95 (0.94, 0.96) 
     15       0.77 (0.46, 0.95) 0.97 (0.96, 0.98) 0.26 (0.20, 0.32)  0.97 (0.96, 0.98) 
Khalid-de Bakkar, 
2011 (39) 
Prospective cross 
sectional 
University hospital 
based screening 
program 
Not reported 329 OC Sensor 54.6 (50 to 65) 1 9 Prior Unknown NA 11.55% NA 38 NA NA 0.16 (0.06, 0.31) 0.97 (0.94, 0.99) 
     15       NA NA 0.28 (0.15, 0.46) 0.95 (0.92, 0.97) 
Omata 2011 (40) Retrospective 
cross sectional 
University hospital 
based prevention 
clinic 
Not reported 1085 OC Sensor 64 (Not provided) 1 5 Prior Yes 0.74%  5.81% 8 63 0.75 (0.35, 0.97) 0.77 (0.74, 0.80) 0.48 (0.35, 0.61) 0.77 (0.74, 0.80) 
    10       0.75 (0.35, 0.97) 0.87 (0.85, 0.89) 0.33 (0.22, 0.46) 0.87 (0.85, 0.89) 
    15       0.50 (0.16, 0.84) 0.92 (0.90, 0.94) 0.19 (0.10, 0.31) 0.92 (0.90, 0.94) 
    20       0.50 (0.16, 0.84) 0.94 (0.92, 0.95) 0.19 (0.10, 0.31) 0.94 (0.92, 0.95) 
    25       0.25 (0.03, 0.65) 0.96 (0.95, 0.97) 0.19 (0.10, 0.31) 0.96 (0.95, 0.97) 
    30       0.25 (0.03, 0.65) 0.97 (0.96, 0.98) 0.19 (0.10, 0.31) 0.97 (0.96, 0.98) 
de Wijkerslooth 2012 
(41) 
Prospective cross 
sectional 
Random sample - 
population based 
screening 
Netherlands 
Research and 
Development & 
Center for 
Translational 
Molecular Medicine 
1256 OC Sensor NA (Not provided) 1 10 Prior Yes 0.64%  8.84% 8 111 0.88 (0.47, 1.00) 0.93 (0.92, 0.95) 0.34 (0.26, 0.44) 0.93 (0.92, 0.95) 
    15       0.75 (0.35, 0.97) 0.94 (0.92, 0.95) 0.30 (0.21, 0.39) 0.94 (0.92, 0.95) 
    20       0.75 (0.35, 0.97) 0.94 (0.93, 0.95) 0.28 (0.20, 0.37) 0.94 (0.93, 0.95) 
Brenner 2013 (42) Prospective cross 
sectional 
Regional 
colonoscopy 
screening program 
German Research 
Foundation & 
Federal Ministry of 
2235 RIDASCREEN 
Haemo/Haptoglobin 
NA (Not provided) 1 2 Prior Yes 0.67%  9.26% 15 207 0.53 (0.27, 0.79) 0.97 (0.96, 0.98) 0.18 (0.13, 0.24)  0.97 (0.96, 0.98) 
  RIDASCREEN Hemo   2       0.60 (0.32, 0.84) 0.97 (0.96, 0.98) 0.21 (0.16, 0.27) 0.97 (0.96, 0.98) 
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 OC Sensor   20       0.73 (0.45, 0.92) 0.97 (0.97, 0.98) 0.22 (0.17, 0.29) 0.97 (0.97, 0.98) 
Chiu 2013 (43) Prospective cross 
sectional 
University hospital 
based prevention 
clinic 
Department of 
Health of Taiwan 
18297 OC Light 59.8 (50 to 70+) 1 10 Prior Yes 0.15%  3.45% 28 632 0.79 (0.59, 0.92) 0.94 (0.93, 0.94) 0.28 (0.25, 0.32) 0.94 (0.93, 0.94) 
Ng 2013 (44) Prospective cross 
sectional 
University hospital 
based prevention 
clinic 
Hong Kong Jockey 
Club 
4539 FIT Hemosure 57.68 (50 to 70) 1 50 Prior Yes 0.48%  4.82% 22 219 0.55 (0.32, 0.76) 0.91 (0.90, 0.92) 0.39 (0.32, 0.46) 0.91 (0.90, 0.92) 
Chen 2014 (45) Retrospective 
cross sectional 
Hospital based CRC 
screening program 
Not reported 6096 OC Light 53.65 (40 to 87) 1 10 Prior Yes 0.21%  3.95% 13 241 0.69 (0.39, 0.91) 0.97 (0.97, 0.98) 0.20 (0.15, 0.25) 0.97 (0.97, 0.98) 
Cubiella 2014 (46) †† Retrospective 
cross sectional 
3 Tertiary care 
hospitals in Spain 
Government 
funded‡ 
722 OC Sensor 56.9 (50 to 69) 1 20 Prior Yes 0.42%  11.63% 3 84 1.00 (0.29, 1.00) 0.96 (0.94, 0.98) 0.27 (0.18, 0.38) 0.96 (0.94, 0.98) 
Hernandez 2014 (47) Prospective cross 
sectional 
3 Tertiary care 
hospitals in Spain 
Government 
funded‡ 
779 OC Sensor 57.55 (50 to 69) 2 10 Prior Yes 0.64%  11.81% 5 92 1.00 (0.48, 1.00) 0.91 (0.89, 0.93) 0.39 (0.29, 0.50) 0.91 (0.89, 0.93) 
     15       1.00 (0.48, 1.00) 0.93 (0.90, 0.95) 0.37 (0.27, 0.48) 0.93 (0.90, 0.95) 
     20       1.00 (0.48, 1.00) 0.93 (0.91, 0.95) 0.34 (0.24, 0.44) 0.93 (0.91, 0.95) 
     23       1.00 (0.48, 1.00) 0.94 (0.91, 0.95) 0.33 (0.23, 0.43) 0.94 (0.91, 0.95) 
     30       0.80 (0.84, 1.00) 0.94 (0.92, 0.96) 0.29 (0.20, 0.40) 0.94 (0.92, 0.96) 
Imperiale 2014 (48) Prospective cross 
sectional 
90, private practice 
and academic sites 
in US 
Exact Sciences  9989 OC-FIT-CHEK NA (50 to ≥75) 1 20 Prior Yes 0.65%  7.58% 65 757 0.74 (0.62, 0.84) 0.95 (0.94, 0.95) 0.24 (0.21, 0.27) 0.95 (0.94, 0.95) 
Stegeman 2014 (49) Prospective cross 
sectional 
Random sample, 
population based 
Dutch Ministry of 
Health 
1112 OC Sensor 60.6 (50 to 75) 1 10 Unknown Unknown 0.63%  8.45% 7 94 0.86 (0.42, 1.00) 0.94 (0.92, 0.95) 0.32 (0.23, 0.42) 0.94 (0.92, 0.95) 
Aniwan 2015 (50) Prospective cross 
sectional 
University hospital-
based screening 
program 
University 
Endowment Fund 
948 SD Bioline FOB 60.6 (50 to 75) 1 10 Prior Yes 0.74%  10.44% 7 99 0.86 (0.42, 1.00) 0.74 (0.71, 0.77) 0.49 (0.38, 0.59) 0.74 (0.71, 0.77) 
Chang 2016 (51) Prospective cross 
sectional 
University hospital-
based screening 
program 
Ministry of Health 
and Welfare of 
Taiwan 
6109 OC Sensor 59 (50 to ≥70) 1 10 Prior Yes NA 5.55% NA 339 NA NA 0.32 (0.28, 0.38) 0.91 (0.90, 0.92) 
     15       NA NA 0.25 (0.20, 0.29) 0.95 (0.94, 0.95) 
     20       NA NA 0.21 (0.17, 0.26) 0.96 (0.96, 0.97) 
Chiu 2016 (52) Prospective cross 
sectional 
Multinational Not reported 3958 OC Sensor 57.8 (40 to ≥70) 1 20 Prior Yes 0.45%  5.26% 18 208 0.94 (0.73, 1.00) 0.68 (0.66, 0.69) 0.61 (0.54, 0.67) 0.68 (0.66, 0.69) 
Siripongpreeda 2016 
(53) 
Prospective cross 
sectional 
Hospital based 
screening program 
Hospital Research 
Grant 
1404 FOB one-step 56.9 (50 to 65) 1 6 Prior Yes 1.28%  6.62% 18 93 0.56 (0.31, 0.79) 0.96 (0.95, 0.97) 0.07 (0.02, 0.14) 0.96 (0.95, 0.97) 
Aniwan 2017 (54)† Prospective cross 
sectional 
6 University 
hospital based 
health promotion 
programs in 
Thailand 
National Research 
Council of 
Thailand, Health 
Systems Research 
Institute &  
International 
Research 
Integration Grant 
1713 OC Sensor 59.4 (50 to 75) 1 10 Prior Yes 0.88%  8.17% 15 140 0.87 (0.60, 0.98) 0.91 (0.89, 0.92) 0.26 (0.19, 0.34) 0.91 (0.89, 0.92) 
     20       0.80 (0.52, 0.96) 0.95 (0.94, 0.96) 0.18 (0.12, 0.25) 0.95 (0.94, 0.96) 
     30       0.80 (0.52, 0.96) 0.96 (0.95, 0.97) 0.11 (0.07, 0.18) 0.96 (0.95, 0.97) 
Brenner 2017 (55) Prospective cross 
sectional 
Regional 
colonoscopy 
screening program 
German Research 
Council 
3437 FOB Gold NA (50 to 79) 1 17 Prior Yes 0.84%  10.30% 29 354 0.97 (0.82, 1.00) 0.94 (0.93, 0.95) 0.37 (0.32, 0.43) 0.94 (0.93, 0.95) 
Kim 2017 (56) Retrospective 
cross sectional 
Health Center 
Screening Program, 
2 centers in Korea 
Not reported 4374 OC Sensor NA (Not provided) 1 20 Prior Unknown 0.25% 4.00% 11 175 0.63 (0.31, 0.89) 0.97 (0.96, 0.97) 0.19 (0.14, 0.26)  0.97 (0.96, 0.97) 
Shapiro 2017 (57) Prospective cross 
sectional 
2 University 
hospital-based 
screening programs 
Center for Disease 
Control & 
Prevention 
947 OC FIT-CHEK NA (50 to 75) 1 20 Prior Yes 0.21%  5.39% 2 51 0.00 (0.00, 0.84) 0.98 (0.97, 0.99) 0.16 (0.07, 0.29) 0.98 (0.97, 0.99) 
 
984 InSure FIT 
 
2    0.20%  5.18%   0.50 (0.01, 0.99) 0.97 (0.96, 0.98) 0.26 (0.14, 0.40) 0.97 (0.95, 0.98) 
Brenner 2018 (58) Prospective cross 
sectional 
Regional 
colonoscopy 
screening program 
German Research 
Council & Federal 
Ministry of 
Education and 
Research 
3211 FOB Gold NA (50 to 79) 1 10 Prior Yes 0.78% 8.91% 25 286 0.96 (0.80, 1.00) 0.88 (0.87, 0.89) 0.48 (0.42, 0.54) 0.88 (0.87, 0.89) 
     20       0.92 (0.74, 0.99) 0.95 (0.94, 0.96) 0.34 (0.28, 0.40) 0.94 (0.94, 0.96) 
     30       0.88 (0.69, 0.97) 0.97 (0.96, 0.97) 0.28 (0.23, 0.34) 0.97 (0.96, 0.97) 
 
AA: Advanced Adenoma; CI: 95% Confidence Interval; CRC: colorectal cancer; FIT: fecal immunochemical test; NA: Not Applicable; µg/g: microgram of hemoglobin per gram of stool 
*6 people in the ≤20 age group, 3 in the ≥81 age group 
†Numbers of CRCs and AAs calculated from percentages 
‡Sponsor had no role in design, analysis, or in manuscript preparation 
†† Received communication from authors with absolute numbers 
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Appendix Table 3. I2 Values for Sensitivity and Specificity 
 FIT Threshold µg/g Colorectal Cancer  Advanced Adenomas I² Sensitivity, Specificity  I² Sensitivity, Specificity <10 61.5%, 99.5%  95.6%, 99.4% =10 21.1%, 99.0%  91.2%, 98.9% >10 <20 72.2%, 96.9%  66.0%, 96.5% =20 68.7%, 99.5%  91.7%, 99.5% >20 66.6%, 95.4%  81.2%, 95.4% 
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Appendix Table 4. Frequencies of Indeterminate FIT Results and Indeterminate Colonoscopies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 *Due to poor prep quality and/or incomplete colonoscopy  † 118 (26.4%) of 447 participants were excluded because of unavailable FIT results, colonoscopy that was either incomplete or of poor quality preparation, or both reasons.  ‡ 8.7% excluded from analysis due to incomplete or missing information  
  
Study, Year (ref) Indeterminate FIT Results  Indeterminate colonoscopies* Nakama, 2001 (28) Not provided Not provided Cheng, 2002 (29) Not provided Not provided Sohn, 2004 (30) Nor provided Not provided Morikawa, 2005 (31) Not provided 1.8%  Nakazato, 2006 (32) Not provided 1.4% Graser, 2009 (33) Not provided 0.64% Brenner, 2010 (34) Not provided Not provided Park, 2010 (35) Not provided 0.12% Parra-Blanco, 2010 (36) Not provided 4.1% Chiang, 2011 (37) Not provided 0.64% Haug, 2011 (38) 2.0% “without FOBT result” 5.5% Khalid-de Bakkar, 2011 (39) Not provided Not provided† Omata, 2011 (40) 7.1% “unavailable” 0.93% de Wijkerslooth, 2012 (41) Not provided Not provided Brenner, 2013 (42) Not provided Not provided Chiu, 2013 (43) Not provided 1.7% Ng, 2013 (44) Not provided Not provided Chen, 2014 (45) Not provided Not provided‡ Cubiella, 2014 (46) Not provided Not provided Hernandez, 2014 (47) Not provided Not provided Imperiale, 2014 (48) 0.31% insufficient hemoglobin 1.76% Stegeman, 2014 (49) Not provided Not provided Aniwan, 2015 (50) Not provided 0.95% Chang, 2016 (51) Not provided 1.98% Chiu, 2016 (52) Not provided Not provided Siripongpreeda, 2016 (53) Not provided Not provided Aniwan, 2017 (54) Not provided 0.7% Brenner, 2017 (55) Not provided Not provided Kim, 2017 (56) Not provided 8.9% Shapiro, 2017 (57) Not provided Not provided Brenner, 2018 (58)  Not provided 0.9% 
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Appendix Figure 1. QUADAS-2 Study Quality Stacked Bar Charts 
 
Q1. Was a consecutive or random sample of patients enrolled? 
Q2. Was a case-control design avoided? 
Q3. Did the study avoid inappropriate exclusions? 
Q4. Could the selection of patients have introduced bias? 
Q5. Are there concerns that the included patients do not match the review question? 
Q6. Were the index test results interpreted without knowledge of the results of the reference standard? 
Q7. If a threshold was used, was it pre-specified? 
Q8. Could the conduct or interpretation of the index test have introduced bias?       
Q9. Are there concerns that the index test, its conduct, or interpretation differ from the review question? 
Q10. Is the reference standard likely to correctly classify the target condition? 
Q11. Were the reference standard results interpreted without knowledge of the results of the index test? 
Q12. Could the reference standard, its conduct, or its interpretation have introduced bias? 
Q13. Are there concerns that the target condition as defined by the reference standard does not match the review question? 
Q14. Was there an appropriate interval between index test(s) and reference standard? 
Q15. Did all patients receive a reference standard? 
Q16. Did all patients receive the same reference standard? 
Q17. Were all patients included in the analysis? 
Q18. Could the patient flow have introduced bias?  
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Appendix Figure, 2. Receiver Operating Characteristic Curves by FIT Threshold 
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Appendix Figure 3a. OC Sensor Summary-level Test Characteristics by Threshold for Colorectal Cancer 
CI: 95% Confidence Interval; CRC: Colorectal Cancer; µg/g: microgram of hemoglobin per gram of stool  
All results generated using a bivariate model 
 
Appendix Figure 3b. OC Sensor Summary-level Test Characteristics by Threshold for Advanced Adenoma 
AA: Advanced Adenoma; CI: 95% Confidence Interval; µg/g: microgram of hemoglobin per gram of stool 
All results generated using a bivariate model 
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Appendix Figure 4a. OC Light Summary-level Test Characteristics by Threshold for Colorectal Cancer 
CI: 95% Confidence Interval; CRC: Colorectal Cancer; µg/g: microgram of hemoglobin per gram of stool 
All results generated using a bivariate model 
 
 
Appendix Figure 4b. OC Light Summary-level Test Characteristics by Threshold for Advanced Adenoma 
AA: Advanced Adenoma; CI: 95% Confidence Interval; µg/g: microgram of hemoglobin per gram of stool 
All results generated using a bivariate model 
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Appendix Figure 5a. OC Hemodia Summary-level Test Characteristics by Threshold for Colorectal Cancer 
CI: 95% Confidence Interval; CRC: Colorectal Cancer; µg/g: microgram of hemoglobin per gram of stool  
All results generated using a bivariate model 
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Appendix Figure 5b. OC Hemodia Summary-level Test Characteristics by Threshold for Advanced Adenoma 
AA: Advanced Adenoma; CI: 95% Confidence Interval; µg/g: microgram of hemoglobin per gram of stool  
All results generated using a bivariate model 
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Appendix Figure 6a. Summary-level Test Characteristics by Threshold for Other FITs (Colorectal Cancer) 
CI: 95% Confidence Interval; CRC: Colorectal Cancer; µg/g: microgram of hemoglobin per gram of stool  
All results generated using a bivariate model 
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Appendix Figure 6b. Summary-level Test Characteristics by Threshold for Other FITs (Advanced Adenoma) 
AA: Advanced Adenoma; CI: 95% Confidence Interval; µg/g: microgram of hemoglobin per gram of stool 
All results generated using a bivariate model 
 
 
 
 
 
 
 
 
